The FDA initiated Project Optimus and issued guidance for dose optimization, recommending randomized parallel dose-response cohorts to generate additional data at promising dose levels and implies that different dosages may be needed for different indications. In addition to dose optimization, with recent advancements in precision medicine and cancer biology, the development of cancer...
Basket trials examine the efficacy of a single intervention simultaneously in several patient subgroups. They are currently mostly applied in oncology, where the subgroup assignment is based on medical characteristics such as a common biomarker. This can result in small sample sizes within subgroups that are also likely to differ. Several designs for the analysis of basket trials have been...
Modern therapeutic agents in cancer therapy often target specific genetic traits of the tumor. Whenever these traits are independent of the tissue in which the tumor is located, the therapeutic agent may be tissue-agnostic, meaning that it can be applied regardless of location. Clinical trials for such tissue-agnostic therapies often have small sample sizes. Hence, it is efficient to recruit...
Background:
A substantial proportion of clinical research waste originates from fundamental methodological flaws—improper study design, insufficient power, inappropriate statistical methods, and non-compliance with reporting guidelines. While many AI tools attempt to support data analysis, none address the critical upstream phase: validating methodology before data collection. To address this...
Confidence distributions are a frequentist alternative to Bayesian posterior distributions. They summarize the knowledge and uncertainty about an unknown model parameter in the form of a probability distribution on the parameter space, just like a posterior distribution, without assuming that the parameter of interest is a random variable. Although confidence distributions are a relatively old...
